Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767354 | 1.00 | IRAK4 (0.42) | IRAK4HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL522830 | 0.86 | IRAK4 (0.40) | IRAK4HTR2ASLC6A4HTR2CHTR2B | |
| SCHEMBL17449413 | 0.85 | IRAK4 (0.37) | IRAK4HTR7HTR2AHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL17764544 | 0.84 | IRAK4 (0.37) | IRAK4HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL18766036 | 0.81 | IRAK4 (0.36) | IRAK4HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL24713780 | 0.80 | IRAK4 (0.43) | IRAK4HTR7HTR2AHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL17764407 | 0.79 | IRAK4 (0.36) | IRAK4HTR7HTR2AHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL17764408 | 0.79 | IRAK4 (0.36) | IRAK4HTR7HTR2AHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL31592712 | 0.79 | IRAK4 (0.36) | IRAK4HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL15354786 | 0.78 | IRAK4 (0.49) | IRAK4HTR7HTR2AHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | IRAK4 548/4885HTR7 1830/4885HTR2A 3250/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | IRAK4 134/4885HTR7 2158/4885HTR2A 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.